CERo Therapeutics Warrants
CEROW
CEROW was delisted on the 30th of October, 2025.
30 hedge funds and large institutions have $6.98M invested in CERo Therapeutics Warrants in 2021 Q4 according to their latest regulatory filings, with 30 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$173K |
| 2 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$138K |
| 3 |
SCM
Saba Capital Management
New York
|
+$136K |
| 4 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$115K |
| 5 |
ACM
Atalaya Capital Management
New York
|
+$104K |
Top Sellers
CEROW Hedge Fund Activity: Q4 2021 in Review
30 of the 6,519 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics Warrants (CEROW) for Q4 2021, worth a combined $6.98M.
Buyers outnumbered sellers: 30 funds opened new CEROW positions and 0 closed out — a net gain of 30 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $173K.
- 30 institutional investors held CERo Therapeutics Warrants (CEROW) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $6.98M of CERo Therapeutics Warrants stock for Q4 2021.
- 30 funds opened new CERo Therapeutics Warrants positions in Q4 2021 and 0 closed out, a net change of +30 holders.
- The largest CERo Therapeutics Warrants buyer in Q4 2021 was Citadel Advisors, an estimated $173K added.
Based on aggregated 13F filings for Q4 2021.